

DAFTAR PUSTAKA

1. Andary MT, Klein MJ. Guillain-Barre Syndrome. 2021;1–23.
2. Asmedi A, Satiti S, Silalahi LM. Peran Pemeriksaan Elektrofisiologi Dalam Diagnosis Sindrom Miller-Fisher. *Callosum Neurol J*. 2020;3:71–7.
3. Tham SL, Prasad K, Umapathi T. Guillain–Barré syndrome mimics. *Brain Behav*. 2018;8:1–5.
4. Akbayram S, Do M, Akgün C, Peker E, Say R, Aktar F, et al. Clinical features and prognosis with Guillain-Barré syndrome. 2011;14.
5. Wang Y, Lang W, Zhang Y, Ma X, Zhou C, Zhang HL. Long-term prognosis of Guillain-Barré syndrome not determined by treatment options? *Oncotarget*. 2017;8:79991–80001.
6. Cabrero FR, Morrison EH. Miller Fisher Syndrome. *StatPearls* [Internet]. 2022 [cited 2023 Jan 25]; Available from: <https://www.ncbi.nlm.nih.gov/books/NBK507717/>
7. Papri N, Islam Z, Leonhard SE, Mohammad QD, Endtz HP, Jacobs BC. Guillain–Barré syndrome in low-income and middle-income countries: challenges and prospects. Vol. 17, *Nature Reviews Neurology*. Springer US; 2021. p. 285–96.
8. M. Hussein L, H. Ali S, H. Mohammed N. Electrophysiological evaluation of Guillain–Barre syndrome subtypes in childhood. *J Fac Med*. 2017;59:60–4.
9. Hughes RA, Cornblath DR. Guillain-Barré Syndrome. *Continuum (Minneap Minn)*. 2020;26:1184–204.
10. Mitsui Y, Kusunoki S, Arimura K, Kaji R, Kanda T, Kuwabara S, et al. A multicentre prospective study of Guillain-Barré Syndrome in Japan: A focus on the incidence of subtypes. *J Neurol Neurosurg Psychiatry*. 2015;86:110–4.
11. Dourado Júnior MET, Fernandes UT, Ramos ES, Vital ALF, Urbano JCC, Queiroz JW, et al. Egos has a reduced capacity to predicts GBS prognosis in Northeast Brazil. *Acta Neurol Scand*. 2018;138:459–62.
12. Wakerley BR, Uncini A, Yuki N. Guillain-Barré and miller fisher syndromes - New diagnostic classification. *Nat Rev Neurol*. 2014;10:537–44.
13. Leonhard SE, Mandarakas MR, Gondim FAA, Bateman K, Ferreira MLB, Cornblath DR, et al. Diagnosis and management of. *Nat Rev Neurol*. 2019;
14. Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. *Lancet*. 2016;388:717–27.
15. Ulfa M, Widowati T, Triono A. Erasmus Guillain-Barre Syndrome Outcome Score (EGOS) to predict functional outcomes. *Paediatr Indones*. 2022;62:130–7.
16. Dimachkie MM, Barohn RJ. Guillain-Barré Syndrome. *Curr Treat Options Neurol*.



17. Brusa R, Faravelli I, Gagliardi D, Magri F, Cogiamanian F, Saccomanno D, et al. Ophthalmoplegia due to Miller Fisher syndrome in a patient with myasthenia gravis. *Front Neurol.* 2019;10:823.
18. Kieseier BC, Hartung HP, Wiendl H. Immune circuitry in the peripheral nervous system. *Curr Opin Neurol.* 2006;19:437–45.
19. Hadden RDM, Karch H, Hartung HP, Zielasek J, Weissbrich B, Schubert J, et al. Preceding infections, immune factors, and outcome in Guillain-Barré syndrome. *Neurology.* 2001;56:758–65.
20. Urlapu KS, Saad M, Bhandari P, Micho J, Hassan MT. Miller Fisher Variant of Guillain-Barré Syndrome: A Great Masquerader. *Cureus* [Internet]. 2020 [cited 2023 Jan 31];12. Available from: <https://www.cureus.com/articles/30922-miller-fisher-variant-of-guillain-barr-syndrome-a-great-masquerader>
21. Shibeshi MS, Mengesha AA, Gari KT. Pediatric Guillain-Barré Syndrome in a Resource Limited Setting: Clinical Features, Diagnostic and Management Challenges, and Hospital Outcome. *Pediatr Heal Med Ther* [Internet]. 2023;Volume 14:107–15. Available from: <https://doi.org/10.2147/PHMT.S401461>
22. Tsurayya Z. Karakteristik Demografis dan Klinis Guillain Barre Syndrome. *Fak Kedokteran, Kesehat Masyarakat, dan Keperawatan Univ Gadjah Mada.* 2020;
23. Yoon B-A, Bae JS, Kim JK. Electrognostic findings of Guillain-Barré syndrome. *Ann Clin Neurophysiol* [Internet]. 2020 [cited 2025 Mar 11];22:13. Available from: <http://www.e-acn.org>
24. van Doorn PA. Diagnosis, treatment and prognosis of Guillain-Barré syndrome (GBS). *Press Medicale.* 2013;42:e193–201.
25. Draak THP, Gorson KC, Vanhoutte EK, van Nes SI, van Doorn PA, Cornblath DR, et al. Does ability to walk reflect general functionality in inflammatory neuropathies? *J Peripher Nerv Syst.* 2016;21:74–81.
26. Wang Y, Zhang HL, Wu X, Zhu J. Complications of Guillain-Barré syndrome. *Expert Rev Clin Immunol.* 2016;12:439–48.
27. Bernsen RAJAM, De Jager AEJ, Kuijter W, Van Der Meché FGA, Suurmeijer TPBM. Psychosocial dysfunction in the first year after Guillain-Barré syndrome. *Muscle and Nerve.* 2010;41:533–9.
28. Epstein SK. Respiratory muscle weakness due to neuromuscular disease: Management. *UpToDate.* 2016;1–14.
29. Roodbol J, De Wit MCY, Aarsen FK, Catsman-Berrevoets CE, Jacobs BC. Long-term outcome of Guillain-Barré syndrome in children. *J Peripher Nerv Syst.* 2014;19:121–6.
30. Roubenoff RA, Borel CO, Hanley DF. Hypermetabolism and hypercatabolism in Guillain-Barre syndrome. *J Parenter Enter Nutr.* 1992;16:464–72.



31. Zhang B, Wu X, Shen D, Li T, Li C, Mao M, et al. The clinical characteristics and short-term prognosis in elderly patients with Guillain-Barré syndrome. *Med (United States)*. 2017;96:1–6.
32. Doets AY, Jacobs BC, van Doorn PA. Advances in management of Guillain–Barré syndrome. *Curr Opin Neurol*. 2018;31:541–50.
33. Noioso CM, Bevilacqua L, Acerra GM, Della Valle P, Serio M, Vinciguerra C, et al. Miller Fisher syndrome: an updated narrative review. *Front Neurol*. 2023;14.
34. McDonnell EP, Altomare NJ, Parekh YH, Gowda RC, Parikh PD, Lazar MH, et al. COVID-19 as a trigger of recurrent Guillain–Barré syndrome. *Pathogens*. 2020;9:1–9.
35. Altered Immunocompetence | Vaccines & Immunizations | CDC [Internet]. CDC Guidelines. 2023 [cited 2025 Mar 8]. Available from: <https://www.cdc.gov/vaccines/hcp/imz-best-practices/altered-immunocompetence.html>
36. Rajabally YA, Uncini A. Outcome and its predictors in Guillaine-Barré syndrome. *J Neurol Neurosurg Psychiatry*. 2012;83:711–8.
37. Barzegar M, Toopchizadeh V, Maher MHK, Sadeghi P, Jahanjoo F, Pishgahi A. Predictive factors for achieving independent walking in children with Guillain-Barre syndrome. *Pediatr Res*. 2017;82:333–9.
38. van Koningsveld R, Steyerberg EW, Hughes RA, Swan A V., van Doorn PA, Jacobs BC. A clinical prognostic scoring system for Guillain-Barré syndrome. *Lancet Neurol*. 2007;6:589–94.
39. Kim B-R, Lim J-H, Lee SA, Park S, Koh S-E, Lee I-S, et al. Usefulness of the Scale for the Assessment and Rating of Ataxia (SARA) in Ataxic Stroke Patients. *Ann Rehabil Med*. 2011;35:772.
40. Harbo T, Andersen H. Neuromuscular effects and rehabilitation in Guillain-Barré syndrome. In: Zika Virus Impact, Diagnosis, Control, and Models: Volume 2: The Neuroscience of Zika Virus. Academic Press; 2021. p. 143–9.
41. Torres-Reyes AB, Reyes-Hernández I, Domínguez-Ramírez OA, Tellez-Lopez AM. Use of Biomedical Engineering for Rehabilitation of Patients with Disability Caused by Guillain-Barré Syndrome: a Systematic Review. *Rev Mex Ing Biomed*. 2024;45:43–59.
42. Okoromah CAN, Ekure EN, Lesi FEA, Okunowo WO, Tijani BO, Okeiyi JC. Prevalence, profile and predictors of malnutrition in children with congenital heart defects: A case-control observational study. *Arch Dis Child*. 2011;96:354–60.
43. De Souza Menezes F, Leite HP, Koch Nogueira PC. Malnutrition as an independent predictor of clinical outcome in critically ill children. *Nutrition*. 2012;28:267–70.
44. Verduci E, Köglmeier J. Immunomodulation in Children: The Role of the Diet. *J Pediatr Gastroenterol Nutr*. 2021;73:293–8.
45. Chou E, Lindeback R, D’Silva AM, Sampaio H, Neville K, Farrar MA. Growth and nutrition in pediatric neuromuscular disorders. *Clin Nutr* [Internet]. 2021;40:4341–8.



Available from: <https://doi.org/10.1016/j.clnu.2021.01.013>

46. Medeiros P, Zequinão MA, Silva WR, Maciel IR, Cardoso FL. Behavioral and Emotional Problems in Children With Poor Motor Skills: According To Parental Emic Perception. *J Phys Educ.* 2022;33:1–12.
47. Murphy JM, Bergmann P, Chiang C, Sturner R, Howard B, Abel MR, et al. The PSC-17: Subscale scores, reliability, and factor structure in a new national sample. *Pediatrics.* 2016;138.
48. Peral Quirós A, Acebrón F, del Carmen Blanco Valero M LÁF. Recurrencia del síndrome de Miller Fisher : descripción de un caso Recurrent Miller Fisher syndrome : Case report. *Neurologia.* 2021;36:561–2.
49. Jang Y, Choi JH, Chae JH, Lim BC, Kim SJ, Jung JH. Pediatric miller fisher syndrome; Characteristic presentation and comparison with adult Miller Fisher syndrome. *J Clin Med.* 2020;9:1–11.
50. Patel K, Nussbaum E, Sico J, Merchant N. Atypical case of Miller-Fisher syndrome presenting with severe dysphagia and weight loss. *BMJ Case Rep.* 2020;13:17–20.
51. Ooi ST, Ahmad A, Yaakub A. Recurrent Miller Fisher Syndrome. *Cureus* [Internet]. 2022;14:4–7. Available from: <https://www.cureus.com/articles/101272-recurrent-miller-fisher-syndrome>